Analytical Data
-
Gene name
VAT1
- Application
-
Alternative Names
VAT1；Synaptic vesicle membrane Protein VAT-1 homolog
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q99536
-
Expression Region
1-393aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MSDEREVAEA ATGEDASSPP PKTEAASDPQ HPAASEGAAA AAASPPLLRC LVLTGFGGYD KVKLQSRPAA PPAPGPGQLT LRLRACGLNF ADLMARQGLY DRLPPLPVTP GMEGAGVVIA VGEGVSDRKA GDRVMVLNRS GMWQEEVTVP SVQTFLIPEA MTFEEAAALL VNYITAYMVL FDFGNLQPGH SVLVHMAAGG VGMAAVQLCR TVENVTVFGT ASASKHEALK ENGVTHPIDY HTTDYVDEIK KISPKGVDIV MDPLGGSDTA KGYNLLKPMG KVVTYGMANL LTGPKRNLMA LARTWWNQFS VTALQLLQAN RAVCGFHLGY LDGEVELVSG VVARLLALYN QGHIKPHIDS VWPFEKVADA MKQMQEKKNV GKVLLVPGPE KEN
-
Molecular Weight
44 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
VAT1 is a protein that has garnered attention due to its role in various cellular processes, including vesicle transport and neurotransmitter release. It is primarily expressed in the nervous system and is implicated in the regulation of synaptic function. Previous studies have shown that VAT1 interacts with key proteins involved in synaptic vesicle trafficking, suggesting its essential role in maintaining synaptic integrity and functionality. The exploration of VAT1, particularly its recombinant forms, has become increasingly important in understanding its molecular mechanisms and potential therapeutic implications. The ability to produce VAT1 as a recombinant protein allows for detailed structural and functional analyses, enabling researchers to investigate its interactions and post-translational modifications more thoroughly. Furthermore, growing evidence suggests that alterations in VAT1 expression or function may be linked to various neurological disorders, making it a promising candidate for further research in developing novel therapeutic strategies. Understanding VAT1 at the molecular level not only contributes to our knowledge of synaptic biology but also opens up avenues for exploring its potential as a biomarker or target in the context of neurodegenerative diseases and synaptic dysfunction. Therefore, VAT1's significance in synaptic regulation and its involvement in neurological health present exciting opportunities for scientific exploration and therapeutic innovation.
